The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|December 2, 2018
- Pharmaceutical Technology-12-02-2018
- Volume 42
- Issue 12
Pharmaceutical Technology North America, December 2018 (PDF)
Click the title above to open the Pharmaceutical Technology December 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 8 years ago
Sterile, Integrated Hood and Mask for Larger Heads and Hairstylesalmost 8 years ago
Scaling Up and Launching Solid-Dosage Drugsalmost 8 years ago
Developing and Manufacturing Transdermal Patchesalmost 8 years ago
Spray Film Provides Alternative to Patchesalmost 8 years ago
Improving Production: How IT, OT, and Quality Can Collaboratealmost 8 years ago
Manufacturing Considerations for Transdermal Delivery Systemsalmost 8 years ago
Investigation Timeliness vs. Thoroughness: Finding the Right Balancealmost 8 years ago
Microbial Identification Strategies for Bioburden Controlalmost 8 years ago
Fighting Bacterial Resistance with Biologicsalmost 8 years ago
The Key Word: QualityAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement